
    
      Patients with peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot
      be treated successfully with the conventional CHOP regimen. The investigators have been
      proceeding this trial to evaluate the efficacy and safety of the PD-1, chidamide,
      lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory
      peripheral T-cell lymphoma.
    
  